Primary eosinophilic gastrointestinal disorders and allergy: Clinical and therapeutic implications

Carlo Maria Rossi1 | Marco Vincenzo Lenti1 | Stefania Merli1 | Amelia Licari2 | Martina Votto2 | Gian Luigi Marsegla2 | Antonio Di Sabatino1

1First Department of Internal Medicine, IRCCS Fondazione Policlinico San Matteo, University of Pavia, Pavia, Italy
2Department of Clinical-Surgical, Diagnostic and Pediatric Sciences, University of Pavia, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy

Correspondence
Antonio Di Sabatino, Clinica Medica1, Fondazione IRCCS Policlinico San Matteo, Università di Pavia, Viale Golgi 19, 27100 Pavia, Italy.
Email: a.disabatino@smatteo.pv.it

Funding information
University of Pavia, Grant/Award Number: PRIN2017

Abstract
Primary eosinophilic gastrointestinal disorders (EGID) are increasingly prevalent, immune-mediated, chronic conditions which primarily affect pediatric and young adult patients, leading to substantial disease burden, and poor quality of life. EGID may either involve single portions of the gastrointestinal tract (i.e., esophagus, stomach, small bowel, and colon) or a combination. Their strong association with allergic disorders has been recently recognized, and although their shared pathophysiological basis remains partly elusive, this feature greatly impacts the diagnostic and treatment work-up. We herein critically discuss the current knowledge on the association of EGID and allergic disorders, including atopic dermatitis, allergic rhinitis, allergic asthma, and food or drug allergy. In particular, we reviewed the literature focusing on their epidemiology, pathophysiological basis and mechanisms, and diagnostic strategies. Finally, we discuss the currently ongoing clinical trials targeting EGID and allergic diseases, including, among others the monoclonal antibodies dupilumab, mepolizumab, benralizumab, and lirintelimab.

KEYWORDS
Allergy, asthma, atopic dermatitis, food allergy, rhinitis

1 | INTRODUCTION

Primary eosinophilic disorders of the gastrointestinal tract (EGID) encompass a spectrum of diseases characterized by prominent eosinophilic inflammation affecting different regions of the gut that occur in the absence of secondary causes (e.g., infections, drug reactions).1,2 Eosinophils typically show an activated phenotype, and their infiltration leads to symptoms related to organ dysfunction. EGID include some major entities according to the topographical localization of the inflammation, namely eosinophilic esophagitis (EoE), eosinophilic gastritis/gastroenteritis, and eosinophilic colitis, and both the pediatric and adult populations can be affected by these conditions, although with different manifestations in the pediatric and adult populations.3,4

Eosinophilic gastrointestinal disorders are increasingly recognized conditions, the prevalence of which has been probably underestimated so far due to poor awareness and lack of standardized diagnostic criteria.5,6 Also, given that endoscopic examinations are needed for making a definitive diagnosis, the entity of underdiagnosis in pediatric patients is probably more relevant. More in depth, EoE,
with a prevalence of 0.5 to 1/1000 individuals in the general population, is the most frequent among EGID, and hence it is the most studied. It represents the most common cause of chronic dysphagia in children and the most common cause of dysphagia with bolus impaction in adults. In a recent study by Cianferoni et al. conducted in the United States, the prevalence of concomitant atopic diseases was significantly higher in both adults and children, compared to non-EoE patients.

Due to their supposed rarity and the paucity of data, the prevalence of the other disorders belonging to the EGID spectrum is more difficult to ascertain. According to a recent US registry-based study by Dellen et al., the prevalence of eosinophilic gastritis, gastroenteritis and eosinophilic colitis, after the introduction of specific ICD-9 codes, can be estimated to be as high as 6.3/100,000, 8.4/100,000, and 3.3/100,000, respectively. However, this figure is probably underestimated, as this commonly occurs in administrative data-driven studies. As recently reported in a systematic review with meta-analysis, non-esophageal EGIDs affect about 2% of patients referred to the hospitals for gastrointestinal symptoms and the prevalence of atopic comorbidities ranges from 25% to 54% of affected patients.

Eosinophilic esophagitis is a chronic immune-mediated, antigen-driven, disease, and results from the complex interplay between genetic and environmental factors, also including early life exposures to certain factors, leading to epithelial barrier dysfunction, allergic sensitization, and prominent Th2 inflammation. On the contrary, the pathogenesis of EGID not affecting the esophagus is still largely uncertain. Some cellular and molecular features of Th2 inflammation have been demonstrated, particularly with reference to eosinophilic gastroenteritis, but autoimmune factors are also believed to exert a role. However, a comprehensive view of their pathogenesis is still lacking, and this contributes, along with other factors, to the substantial diagnostic delay and therapeutic uncertainty. Moreover, the association with allergic disorders must be considered when managing patients with EGID, as they may share a common etiopathological background and hence some clinical features. In fact, some patterns of disease association are common in these patients, such as the co-occurrence of allergic asthma, rhinitis, and esophageal symptoms, or the occurrence of gastrointestinal symptoms in patients receiving oral immunotherapy for food allergy, or else the occurrence of isolated diarrhea in atopic patients. All these clinical patterns should raise the suspicion of EGID.

Apart from the common association with allergic manifestations, the clinical features of EGID vary according to the gut segment and the layer of the gut wall involved, that is, the mucosa, the muscular layer, or the serosa, and the diagnostic work-up of EGID is primarily based on endoscopy and histopathology. The main clinical features, diagnostic criteria, and currently available therapies for EGID are summarized in Table 1.

The aim of the present review is to provide in a narrative and concise fashion an updated overview about the association between EGID and the whole spectrum of allergic disorders in adults and children, in order to improve diagnosis and treatment of allergic comorbidities in patients with EGID. We also provide a critical update of the ongoing clinical trials regarding therapies for EGID, highlighting potential advantages for concomitant allergic disorders.

2 METHODS

In June and September 2021, we performed a computer-assisted literature search for relevant studies using PubMed. The aim of the search was to find papers dealing with the association of EGID with allergic disorders, focusing on the clinical and therapeutic implications. The research was restricted to papers published in English. The medical subject heading terms used were “EoE,” “eosinophilic gastritis,” “eosinophilic gastroenteritis,” “eosinophilic colitis,” and “atopy,” “asthma,” “allergic rhinitis,” “atopic dermatitis,” “drug allergy,” “eczema,” “environmental allergy.” By using these terms, we found more 3000 papers. Of these, most were unrelated to the review topic and hence were discarded by all authors. We focused on the original, review articles, and case reports/series since database inception, dealing with the association of allergic disorders in EGID, in both the pediatric and the adult settings. We also searched for relevant papers cited in authoritative reviews dealing with EGID in relation to other allergic disorders. Given the narrative, expert-based, nature of the review we did not carry out a systematic review of the literature.

2.1 Eosinophilic esophagitis

Eosinophilic esophagitis has proteiform manifestations and symptoms, which vary with age. While young children and toddlers usually experience vomiting, regurgitation, abdominal pain, feeding refusal, and failure to thrive, adolescents and adults often report dysphagia and food impaction that may be the expression of advanced tissue remodeling. EoE may affect people of any age and gender, but it is more common in young male individuals. It is characterized by the presence of esophageal infiltration in both the proximal and distal esophagus. The disrupted function of the muscularis mucosa layer, which can be shown by ultrasonography, results in symptoms of esophageal dysmotility.

Most of the studies considering the relationship between EGID and asthma are focused on EoE, probably because EoE is the most frequent form of EGID, paralleling the epidemiologic surge of allergic diseases. Several studies have shown that patients with EoE suffer from a significant burden of allergic comorbidities, such allergic rhinitis, asthma, atopic dermatitis, and IgE-mediated food-allergy.

The prevalence of asthma in adult series of EoE patients varies from 25% to 50%, and reaches 60% in pediatric series. Moreover, in a previous meta-analysis considering a large number of individuals it was found that patients with EoE had a significantly increased probability of having asthma (OR 3.01, 95% CI 1.96–4.62, OR 5.09, 95% CI 3.91–8.90, respectively) and allergic rhinitis compared to controls. This strong association has led some authors to consider EoE as “the asthma of the esophagus.”
Table 1: Clinical and endoscopic features, diagnostic criteria, current therapeutic options in eosinophilic gastrointestinal disorders

| Clinical features | Eosinophilic esophagitis | Eosinophilic gastritis/enteritis | Eosinophilic colitis |
|-------------------|--------------------------|---------------------------------|---------------------|
| Symptoms vary with age | Mucosal form: vomiting, abdominal pain, diarrhea, malabsorption, protein-losing enteropathy, iron-deficient anemia, failure to thrive (children), melena. | Abdominal pain | Diarrhea |
| Gastroesophageal reflux disease (heartburn, acid regurgitation), epigastric pain, dysphagia, food impaction, vomiting, weight loss | Muscularis layer form: obstructive symptoms. | Weight loss | Weight loss |
| Therapeutic disorders criteria, in Clinical current endoscopic eosinophilic diagnostic 1 | Serosal form: eosinophil-rich ascites | Anorexia | Anorexia |

| Endoscopic features | Edema | Micronodules | Erythema |
|---------------------|-------|-------------|---------|
| Linear oriented creases (furrowing) | Erosion | Loss of vascularity | |
| Mucosal rings (feline esophagus) | Mucosal hyperemia | Lymphonodular hyperplasia | |
| Exudates and whitish papules | | | |
| Polyps | | | |
| Strictures | | | |

| Diagnostic criteria | ≥15 Eo/HPF from at least one site (distal, mid, or proximal esophagus) | ≥30 Eo/HPF in ≥5 HPF or ≥70 Eo/HPF in ≥3 HPF (stomach) | ≥100 Eo/HPF (cecum/ascending colon) |
|---------------------|----------------------------------|--------------------------|------------------|
|                      | ≥52 Eo/HPF (duodenum) | ≥56 Eo/HPF (ileum) | ≥84 Eo/HPF (transverse/descending colon) |
|                      | ≥64 Eo/HPF (sigmoid/rectum) | | ≥64 Eo/HPF (sigmoid/rectum) |

| Histopathological features | Eosinophilic inflammation, eosinophil abscess, eosinophil surface layer, basal zone hyperplasia, dilated intercellular spaces, dyskeratotic epithelial cells, lamina propria fibrosis. | Eosinophilic inflammation in different layers | Eosinophil cryptitis/crypt abscesses, crypt architectural abnormalities, increased intraepithelial eosinophils, and eosinophils in muscularis mucosa and submucosa |
|---------------------------|--------------------------------------------------------------------------------|---------------------------------|------------------------------------------------------------------|
| Immunostaining for MCP, ECP, IgE, tryptase | Blunt villi | Immunostaining for MCP, ECP, IgE, tryptase | Immunostaining for MCP, ECP, IgE, tryptase |

| Laboratory parameters | Peripheral blood eosinophilia (not always present) | Peripheral blood eosinophilia (not always present) | Peripheral blood eosinophilia (not always present) |
|-----------------------|---------------------------------------------------|---------------------------------------------------|---------------------------------------------------|

| Differential diagnoses | Infection | Infection | Infection |
|------------------------|-----------|-----------|-----------|
| HES | HES | HES | |
| Neoplasm | Celiac disease | Ulcerative colitis | |
| CTD/SS | Crohn’s disease | Crohn’s disease | |
| Small vessel vasculitis | CTD/SS | CTD/SS | |
| Drug reaction | Small vessel vasculitis | Small vessel vasculitis | |
| | Systemic mastocytosis | Systemic mastocytosis | |
| | Drug reaction | Drug reaction | |

| Association with allergic disorders | +++ | ++ | + |
|-------------------------------------|-----|----|---|

| Predominant allergic phenotype | IgE | IgE | T-cell |
|---------------------------------|-----|-----|--------|
| T-cell | T-cell | T-cell | |

| Therapeutic options | Elemental diet, 6, 4, and 2 FED | Elemental diets | Elemental diet |
|---------------------|---------------------------------|-----------------|---------------|
| Topical glucocorticoid | Topical and systemic glucocorticoid | Topical and systemic glucocorticoid | |
| Proton pump inhibitors | | | |

| Evolution | Esophageal stenosis, bleeding, perforation/rupture, especially if left untreated | Poorly characterized in the long term | Poorly characterized in the long term |
|-----------|--------------------------------------------------------------------------------|---------------------|---------------------|

Abbreviations: CTD, connective tissue disease; FED, food elimination diet; HES, hyper-eosinophilic syndrome; HPF, high power field; SS, systemic sclerosis.

Food allergy has been traditionally linked to EoE, given the strong epidemiologic link between these disorders, the clinical and histological response of EoE to elemental diets, and, more recently, the increased recognition of EoE in patients being treated with oral immunotherapy. The prevalence of IgE-mediated food allergy varies between 25% and nearly 70%. The most frequently implied foods are milk, wheat, soy, egg, nuts, and shellfish. Eczema was also significantly more frequent in patients than controls, (OR 2.85, 95% CI 1.87–4.34).

Finally, in a large cross-sectional, population-based survey conducted in the US, a high prevalence of allergic disorders was observed among 74 EoE children and 89 EoE adults, namely 32.4%
| Author, year, country | Study type | Population | Pathology | Allergy disease | Comments | References |
|-----------------------|------------|------------|-----------|----------------|----------|------------|
| Wright et al., 2018 United States | Prospective, Patients with peanut allergy (n = 21) | Adults | EoE | Food allergy | EoE common in adults with IgE-mediated peanut allergy before OIT | 50 |
| Eckmann et al., 2018 United States | Pilot, prospective, open-label. EoE (n = 8) | Adults | EoE | Food allergy | Only four patients with a positive atopy patch test. No concordance between atopy patch test and EoE | 51 |
| Burk et al., 2017 United States | Prospective, EoE patients with peanut allergy (n = 13) | Adults | EoE | Food allergy | Two patients pretreated with omalizumab developed EoE | 52 |
| Dellon et al., 2015 United States | Prospective, case-control EoE (n = 81), controls (n = 144) | Adults | EoE | Asthma, Rhinitis, Atopic dermatitis, Food allergy | Food allergies more common in EoE while atopy disease had not statistical significance | 27 |
| Sealock et al., 2013 United States | Prospective, EoE patients (n = 31), esophageal eosinophilia without EoE (n = 7), controls (n = 1319) | Adults | EoE | Asthma | Seasonal allergies and esophageal strictures associated with esophageal eosinophilia. Asthma not significantly associated with esophageal eosinophilia or EoE | 53 |
| Joo et al., 2012 Korea | Prospective. EoE patients (n = 8) and controls (n = 114) | Adults | EoE | Asthma, Rhinitis, Atopic dermatitis, Food allergy | A history of allergic rhinitis and atopic dermatitis significantly common in EoE patients | 54 |
| DeBrosse et al., 2011 United States | Retrospective, nested case-control. EoE patients (n = 42), chronic esophagitis (n = 67), controls (n = 100) | Adults | EoE | Rhinitis, Food allergy | Food impaction more common in patients with food allergy. Eczema associated with history of esophageal dilation. Allergic rhinitis, asthma, and food allergy associate with dysphagia. Food allergy more frequent in EoE patients than chronic esophagitis | 55 |
| García-Compean et al., 2011 Mexico | Prospective. EoE patients (n = 6) and controls (n = 144) | Adults | EoE | Atopy | Atopy as an independent predictor of EoE | 56 |
| Ravi et al., 2011 United States | Retrospective. EoE patients (n = 418) and controls (n = 59) | Adults | EoE | Asthma, Rhinitis | Atopy (asthma and allergic rhinitis) more common in patients with ≥15 eos/HPF | 57 |
| Foroutan et al., 2010 Iran | Cross-sectional. EoE patients (n = 6), Adults | EoE | Asthma, Rhinitis | Atopy was more common in EoE, while asthma, urticaria, atopic dermatitis, rhino-conjunctivitis, and... | 58 |
and 37.3%, respectively, had ≥1 current IgE-food allergy, 27.8% and 47.8%, respectively, had asthma, 27.5% and 22.9%, respectively, had atopic dermatitis/eczema, and 43.5% and 41.6%, respectively, had seasonal rhinitis.9

Overall, these findings have led many researchers to include EoE in the spectrum of disorders making up the atopic march, often representing the final step of this progression.32 Of note, the association between food allergy and EoE has been found to be the strongest.32

Several pathophysiological theories have been put forward to explain the association between EoE with atopic disorders, however a consistent picture is still lacking.33 A possible role of aeroallergens in terms of EoE diagnosis/exacerbation has been suggested by clinical studies, showing an association between pollen season and incidence of EoE diagnosis.34 Besides, cases of EoE after sublingual immunotherapy for respiratory allergies have also been observed.20,35,36 The exact mechanistic interpretation of these findings is still incomplete. A direct effect of pollen allergens, but also of food allergens that are cross-reactive topollens, could be present.

A common pathophysiologic feature of EoE and food allergy could be the presence of a shared allergen-restricted Th2 specificity. However, despite these similarities, these conditions display peculiar features, as EoE is usually a life-long disease, whereas food allergy is usually transitory, so it is not uncommon to encounter patients with EoE with a history of food allergy. Moreover, the anti-IgE therapy seems to exert a marginal role in EoE.37,38 These findings imply that the eosinophilic inflammation in EoE is independent of a classical Th2-response and other still unknown factors play a role.

### 2.2 Eosinophilic gastritis and gastroenteritis

Gastritis, enteritis, and gastroenteritis are usually considered as a whole nosologic entity given their clinical similarities and paucity of pathogenetic knowledge. They may show concomitant eosinophilic infiltration of other gut regions, such as the esophagus and the large intestine. Clinical manifestations are proteiform, as already shown in Table 1, depending on which layer of the gut wall is mostly affected. Symptoms could be mild and often overlooked, or could be serious and potentially life-threatening, including abdominal pain, diarrhea, and frank malabsorption.39

Asthma and other allergic diseases, such as allergic rhinitis, have also been described in patients with eosinophilic gastritis or gastroenteritis, but with less convincing evidence compared to EoE. Nonetheless, the frequency of self-reported allergic rhinitis and asthma is still relevant, as high as 63% and 39%, respectively, in a questionnaire-based registry study assessing the prevalence of atopic conditions in 107 patients, adults and children, with these conditions.40

More recently, some case reports have described the association between asthma and eosinophilic gastritis in a few patients with severe asthma, treated with dupilumab or mepolizumab.41,42 Few data pertaining the association between eosinophilic gastritis with food allergy are available, while the majority of the studies has
| Author, year, country | Study type                  | Population                                      | Pathology | Allergy disease                  | Comments                                                                 | References |
|-----------------------|-----------------------------|------------------------------------------------|-----------|----------------------------------|--------------------------------------------------------------------------|------------|
| Votto et al., 2021 Italy | Retrospective              | Children and adolescents                       | EGIDs     | Asthma Rhinitis Atopic dermatitis Food allergy | Allergic comorbidities in approximately 30% of enrolled patients, more frequently observed in children with EoE (36.5%) | 61         |
| Leung et al., 2015 Canada | Prospective. EoE (n = 23), GERD (n = 20), normal superior endoscopy with gastrointestinal symptoms (n = 14) and controls (n = 26) | Children | EoE       | Asthma Rhinitis Atopic dermatitis Food allergy | Rhinitis more common in EoE group                                          | 62         |
| Fuentes-Aparicio et al, 2013 Spain | Randomized clinical trial. Patients with egg allergy (n = 40) | Children | EoE       | Food allergy | One patient developed EoE after egg OIT | 63         |
| Slae et al, 2013 Canada | Cross-sectional, case-control study. EoE patients (n = 102) and controls (n = 167) | Children | EoE       | Asthma Rhinitis Atopic dermatitis Food allergy | Food allergy, (peanuts and tree nuts) allergy to pollen (tree and grass) significantly higher among EoE than controls | 64         |
| Jensen et al, 2013 United States | Case-control. EoE patients (n = 31), GERD (n = 26), and siblings of non-syndromic cleft lip/palate patients (n = 26) | Children | EoE       | Asthma Food allergy | The frequency of food allergies, environmental allergies, and asthma higher for cases with EoE than controls | 65         |
| Sanchez-Garcia et al., 2012 Spain | Retrospective. Patients with milk allergy (n = 110) | Children | EoE       | Food allergy | Three patients developed EoE after milk OIT | 66         |
| Ridolo et al, 2011 Italy | Case report                | Children | EoE       | Food allergy | A child with acute EoE after egg OIT | 67         |
| Cassel et al, 2009 United States | Retrospective charts review. EoE patients (n = 35) and controls (n = 7) | Children | EoE       | Asthma Atopic dermatitis | Atopy, asthma, and eczema were more common in EoE patient than in GERD | 68         |
| Aceves et al, 2009 United States | Prospective, case-control. Patients with EoE (n = 35), GERD (n = 27), allergic patients without EoE (n = 24), and non-allergic patients (n = 14) | Children | EoE       | Asthma Rhinitis Food allergy | Food allergy more common in patients with EoE while asthma and allergic rhinitis were more common in allergic controls | 69         |
evaluated mainly sensitization to food allergens alone. Another limitation is represented by the inclusion of cases of concomitant EoE. The presence of food allergy was ascertained in a pediatric US series in one-ninth of patients with isolated eosinophilic gastritis and one-third in those with eosinophilic gastritis with duodenal eosinophilia. In another US study including 44 patients, children and adults, with eosinophilic gastroenteritis (associated EoE in 30% of the cases) the prevalence of food allergy was 42%. Interestingly, drug allergy was also found in 31% and eczema in 16%.

Overall, the prevalence of atopic disorders in patients with eosinophilic gastritis and gastroenteritis appears to be high, being estimated at 38.5% and 45.6%, respectively.

2.3 | Eosinophilic colitis

Primary eosinophilic colitis is the least frequent disorder among EGID. The absence of internationally agreed diagnostic criteria, including a clear eosinophilic infiltrate threshold, has hampered its identification for a long time. Eosinophilic colitis frequently presents with diarrhea, abdominal pain, anorexia, and weight loss. It has a bimodal age presentation, namely in infancy (at approximately 60 days of age) and during adolescence and early adulthood. Also, it has been associated with a wide range of atopic disorders, including drug allergy, allergic rhinitis, asthma, and food allergy.

In a US administrative database study, Jensen et al. evaluated 404 adult patients with eosinophilic colitis, finding that co-existing allergic conditions were common, being present in 41.8% of the patients. The most commonly reported allergic condition was allergic rhinitis (30%). Asthma was reported in 15% and atopic dermatitis in 6.2% of the patients. In a smaller series of adult patients (n = 22), a lower incidence of both asthma and allergic rhinitis (18%) was reported.

The prevalence of atopic conditions seems to be high also in children, according to the only case series available, which includes almost 50 individuals, and reports that 40% displayed one or more signs of atopy. The same estimate of comorbid atopic conditions has been calculated by Dellon et al. in the aforementioned register-based study.

3 | OUTLOOK

Allergic manifestations are a frequent comorbidity in patients with immune-mediated disorders of the gastrointestinal tract, including classical autoimmune diseases and EGID. The current evidence of the association between EGID and allergic disorders, as discussed above, is summarized in Tables 2–4, for adults, children, and both, respectively.

Allergens can lead to disease exacerbation and allergen elimination results in disease control in a significant proportion of patients. Besides, the control of atopic conditions is important to control EoE. Patients living with EGID should be carefully
| Author, year, country | Study type | Population | Pathology | Allergy disease | Comments | References |
|-----------------------|------------|------------|-----------|----------------|----------|------------|
| Duffey et al., 2016 United States | Retrospective, administrative data. EoE and their relatives ($n = 4,009$) and controls ($n > 100,000$) | Children and adults | EoE | Asthma | Significant familial clustering of asthma and atopic disease (anaphylaxis, atopic dermatitis, allergic rhinitis, and conjunctivitis) in distant relatives of EoE proband | 72 |
| Peterson et al., 2015 United States | Retrospective, case-control. EoE ($n = 4423$) and controls (first- and second-degree relatives, first cousin and spouses of patients) ($n = 22,627$) | Children and adults | EoE | Asthma Rhinitis Atopic dermatitis Food allergy Anaphylaxes | Atopy diseases including anaphylaxes more common in EoE patients and relatives | 73 |
| Mansoor et al., 2016 United States | Administrative data. EoE patients ($n = 7840$), whole population controls ($n = 30,301,440$) | Children and adults | EoE | Asthma Rhinitis Atopic dermatitis Food allergy Drug allergy | Allergic diseases (drug allergy, food allergy, rhinitis, IgE mediated disorder, asthma, sinusitis, dermatitis, eczema, and urticaria) more common in EoE patients | 74 |
| Mulder et al., 2013 Canada | Retrospective, case-control. EoE patients ($n = 44$) and controls ($n = 44$) | Children and adults | EoE | Asthma Rhinitis Atopic dermatitis Food allergy Drug allergy | Atopy more common in EoE patients than controls | 81 |
| Zafra et al., 2013 Spain | Prospective, case-control. EoE ($n = 25$) and controls ($n = 17$) | Children and adults | EoE | Rhinitis Food allergy | EoE patients more likely to have sensibilization to aeroallergens, rhino conjunctivitis, and food allergy | 75 |
| Dellon et al., 2009 United States | Retrospective case-control. EoE patients ($n = 151$), GERD ($n = 226$) | Children and adults | EoE | Asthma Rhinitis Atopic dermatitis Food allergy | Atopy (allergic rhinitis/dermatitis, food allergy, and asthma) was more common in EoE patients and food allergy was considered a reliably predictor factor to discriminate EoE from GERD | 76 |

Abbreviations: EoE, eosinophilic esophagitis; GERD, gastroesophageal reflux disease.
evaluated from a multidisciplinary team, made up by an allergist, a pediatrician, and a gastroenterologist, considering all aspects of Th2 inflammation. Treatment modalities should possibly be tailored to tackle shared molecular pathways.

| Agent                                           | Route of administration | Mechanism of action                      | Condition | Clinical trial number | Phase |
|-------------------------------------------------|------------------------|------------------------------------------|-----------|-----------------------|-------|
| Antihistamines (loratadine and famotidine)      | Oral                   | Histamine-1 (H1) and Histamine-2 (H2) receptor antagonists | EoE       | NCT04248712          | 2     |
| Febuxostat                                      | Oral                   | Non-purine-selective inhibitor of xanthine oxidase | EoE       | NCT02873468          | 2     |
| Omeprazole                                      | Oral                   | PPI                                      | EoE       | NCT04149470          | 4     |
| Fluticasone and omeprazole versus fluticasone alone | Oral               | Anti-inflammatory PPI                      | EoE       | NCT03781596          | 4     |
| Budesonide                                      | Oral                   | Anti-inflammatory                          | EoE       | NCT03245840          | 3     |
| Fluticasone propionate                          | Oral                   | Anti-inflammatory                          | EoE       | NCT04281108          | 3     |
| Mometasone furoate                              | Oral                   | Anti-inflammatory                          | EoE       | NCT04849390          | 2     |
| Mepolizumab                                     | s.c.                   | Anti-IL5 mAb                              | EoE       | NCT03656380          | 2     |
| Benralizumab                                    | s.c.                   | Anti-IL5Ra mAb                            | EoG       | NCT03473977          | 2-3   |
| Benralizumab                                    | s.c.                   | Anti-IL5Ra mAb                            | EoE       | NCT04543409          | 3     |
| Dupilumab                                       | s.c.                   | Anti-IL4/13 mAb                           | EoG       | NCT03678545          | 2     |
| Dupilumab                                       | s.c.                   | Anti-IL4/13 mAb                           | EoE       | NCT03633617          | 3     |
| Dupilumab                                       | s.c.                   | Anti-IL4/13 mAb                           | EoE       | NCT04394351          | 3     |
| Cendakimab                                      | s.c.                   | Anti-IL3 mAb                              | EoE       | NCT04753697          | 3     |
| CALY-002                                        | i.v.                   | Anti-IL15 mAb                             | EoE       | NCT04593251          | 1     |
| Lirentelimab                                    | i.v.                   | Anti-Siglec-8 mAb                         | EoE       | NCT04322708          | 2-3   |
| Lirentelimab                                    | i.v.                   | Anti-Siglec-8 mAb                         | EoG       | NCT04322604          | 3     |
| Lirentelimab                                    | i.v.                   | Anti-Siglec-8 mAb                         | EoG       | NCT03664960          | 2     |
| Lirentelimab                                    | i.v.                   | Anti-Siglec-8 mAb                         | EoG       | NCT04620811          | 3     |
| Lirentelimab                                    | i.v.                   | Anti-Siglec-8 mAb                         | EoE       | NCT04856891          | 3     |
| Etrasimod                                       | Oral                   | Sphingosine 1-phosphate (S1P) receptor     | EoE       | NCT04682639          | 2     |
| Benzimidazolylpicolinoyl                        | Oral                   | Active lanthionine synthetase C-like 2 (LANCL2) | EoE | NCT04835168 | 1     |

Abbreviations: EoD, eosinophilic duodenitis; EoE, eosinophilic esophagitis; EoG, eosinophilic gastritis; EoGE, eosinophilic gastroenteritis; mAb, monoclonal antibody; PPI, proton pump inhibitor.

Notably, a number of clinical trials regarding treatment modalities for EGID are currently ongoing (Table 5). Apart from a few unspecific, non-biologic, molecules, most of the drugs under investigations are monoclonal antibodies, all of them targeting different pathogenic
pathways that, in some cases, are shared with allergic diseases. For example, dupilumab, an anti-interleukin 4 (IL4) receptor alpha monoclonal antibody, has already been approved for the treatment of atopic dermatitis and allergic asthma, while mepolizumab, an anti-IL5 monoclonal antibody, has already been approved for allergic asthma.\textsuperscript{78,79} Moreover, lirentelimab, a monoclonal antibody targeting an inhibitory receptor Siglec-8, could represent an interesting therapeutical agent targeting both the allergic disorders and EGID, since this receptor is present only on mastcells, basophils, and eosinophils, all key players in both disease groups.\textsuperscript{18,80,81} The main molecular targets of monoclonal antibodies are shown in Figure 1.

We do feel that EGID and allergic disorders should be better managed by a multidisciplinary team, given their complex nature, which is not only confined to their possible shared pathophysiological bases, but also includes (i) the high clinical burden, due to their potentially long diagnostic delay and poor quality of life, (ii) the difficult diagnostic work-up, and (iii) the need for specific expertise and competences for their diagnosis. The future clinical research agenda should focus on the identification of non-invasive biomarkers for their diagnosis and their early recognition. The main key messages mentioned in the outlook are summarized in Table 6.\textsuperscript{82}

ACKNOWLEDGMENT
We thank University of Pavia (PRIN2017) for supporting our research projects.

CONFLICT OF INTEREST
None to disclose for all authors.

AUTHOR CONTRIBUTIONS
All authors significantly participated in the drafting of the manuscript or critical revision of the manuscript for important intellectual content and provided approval of the final submitted version.

ORCID
Carlo Maria Rossi \(\text{http://orcid.org/0000-0003-1314-361X}\)
Marco Vincenzo Lenti \(\text{http://orcid.org/0000-0002-6654-4911}\)
Stefania Merli \(\text{http://orcid.org/0000-0003-1677-5778}\)
Amelia Licari \(\text{https://orcid.org/0000-0002-1773-6482}\)
Martina Votto \(\text{https://orcid.org/0000-0002-4271-8649}\)

### TABLE 6 Key messages

1. A multidisciplinary approach for the diagnosis and treatment of EGID is warranted to tackle all the diverse organ manifestations of Th2 inflammation (i.e., skin, nose, and lungs, gastrointestinal tract).
2. The identification of the causal allergen(s) improves disease control.
3. Pathogenesis-targeted therapies aimed at controlling the whole burden of allergic comorbidities within the same patient should be considered.
4. Non-invasive diagnostic biomarkers to enable early diagnosis are needed.
REFERENCES

1. Cianferoni A, Spergel J. Eosinophilic esophagitis and gastroenteritis. Curr Allergy Asthma Rep. 2015;15:58. https://doi.org/10.1007/s11882-015-0558-5

2. Spergel J, Brown-Whitehorn T, Muir A, et al. Medical algorithm: diagnosis and treatment of eosinophilic esophagitis in children. Allergy. 2020;75:1522-1524.

3. Pinetón de Chambrun G, Gonzalez F, Canva J, et al. Natural history of eosinophilic gastroenteritis. Clin Gastroenterol Hepatol. 2011;9:950-956.

4. Straumann A, Aecives S, Blanchard C, et al. Pediatric and adult eosinophilic esophagitis: similarities and differences. Allergy. 2012;67:477-490.

5. Gonsalves N. Eosinophilic gastrointestinal disorders. Clin Rev Allergy Immunol. 2019;57:272-285.

6. Alhmoud T, Hanson J, Parasher G. Eosinophilic gastroenteritis: an underdiagnosed condition. Dig Dis Sci. 2016;61:2585-2592.

7. Dellon ES, Hirano I. Epidemiology and natural history of eosinophilic esophagitis. Gastroenterology. 2018;154:319-332.

8. Capucilli P, Hill DA. Allergic comorbidity in eosinophilic esophagitis: mechanistic relevance and clinical implications. Clin Rev Allergy Immunol. 2019;57:111-127.

9. Cianferoni A, Warren CM, Brown-Whitehorn T, et al. Eosinophilic esophagitis and allergic comorbidities in a US-population-based study. Allergy. 2020;75:1466-1469.

10. Jensen ET, Martin CF, Kappelmann MD, et al. Prevalence of eosinophilic gastritis, gastroenteritis, and colitis: estimates from a national administrative database. J Pediatr Gastroenterol Nutr. 2016;62:36-42.

11. Lenti M, Corazza G. Administrative data for exploring multimorbidity in hospitalised patients. Intern Emerg Med. 2020;15:1161-1163.

12. Licari A, Votto M, Scudeller L, et al. Epidemiology of nonoesophageal eosinophilic gastrointestinal diseases in symptomatic patients: a systematic review and meta-analysis. J Allergy Clin Immunol Pract. 2020;8:1994-2003.

13. Dellon E, Liacouras C, Molina-Infante J, et al. Updated international consensus diagnostic criteria for eosinophilic esophagitis: proceedings of the AGREE conference. Gastroenterology. 2018;155:1022-1033.

14. Votto M, Marseglia G, De Filippo M, et al. Early life risk factors in pediatric EOe: could we prevent this modern disease? Front Pediatr. 2020;8:263.

15. Caldwell J, Collins M, Stucke E, et al. Histologic eosinophilic gastritis is a systemic disorder associated with blood and extragastric eosinophilia, TH2 immunity, and a unique gastric transcriptome. J Allergy Clin Immunol. 2014;134:1114-1124.

16. Talley N. Gut eosinophilia in food allergy and systemic and autoimmune diseases. Gastroenterol Clin North Am. 2008;37:307-332.

17. Lenti MV, Savarino E, Mauro A, et al. Diagnostic delay and misdiagnosis in eosinophilic esophagitis. Dig Liver Dis. 2021;53(12):1632-1639. https://doi.org/10.1016/j.dld.2021.05.017

18. Peterson K, Safroneeva E, Schoepfer A. Emerging therapies for eosinophilic gastrointestinal diseases. J Allergy Clin Immunol Pract. 2021;9:3276-3281.

19. Afrnogenova Y, Rubin T, Patel S, et al. Community private practice clinical experience with peanut oral immunotherapy. J Allergy Clin Immunol Pract. 2020;8:2727-2735.

20. Antico A, Fante R. Esophageal hypereosinophilia induced by grass sublingual immunotherapy. J Allergy Clin Immunol. 2014;133:1482-1484.

21. Collins M, Capocelli K, Yang G. Eosinophilic gastrointestinal disorders pathology. Front Med. 2018;4:261.

22. Schoepfer A, Safroneeva E, Bussmann C, et al. Delay in diagnosis of eosinophilic esophagitis increases risk for stricture formation in a time-dependent manner. Gastroenterology. 2013:145:1230-1236.

23. Muir A, Brown-Whitehorn T, Godwin B, et al. Eosinophilic esophagitis: early diagnosis is the key. Clin Exp Gastroenterol. 2019;12:391-399.

24. Votto M, Castagnoli R, De Filippo M, et al. Behavioral issues and quality of life in children with eosinophilic esophagitis. Minerva Pediatr. 2020;72:424-432.

25. Clarke J, Ahuja N, Fernandez-Becker N, et al. The functional lumen imaging probe in gastrointestinal disorders: the past, present, and future. Ann N Y Acad Sci. 2020;1482:16-25.

26. Capucilli P, Cianferoni A, Grundmeier RW, et al. Comparison of comorbid diagnoses in children with and without eosinophilic esophagitis in a large population. Ann Allergy Asthma Immunol. 2018;121(6):711-716.

27. Dellon ES, Rusin S, Gebhart JH, et al. A clinical prediction tool identifies cases of eosinophilic esophagitis without endoscopic biopsy: a prospective study. Ann J Gastroenterol. 2015;110(9):1347-1354.

28. Chehade M, Jones SM, Pesek RD, et al. Phenotypic characterization of eosinophilic esophagitis in a large multicenter patient population from the consortium for food allergy research. J Allergy Clin Immunol Pract. 2018;6(5):1534-1544.

29. González-Cervera J, Arias A, Redondo-González O, et al. Association between atopic manifestations and eosinophilic esophagitis: a systematic review and meta-analysis. Ann Allergy Asthma Immunol. 2017;118(3):582-590.

30. Virchow J. Eosinophilic esophagitis: asthma of the esophagus? Dig Dis. 2014;32:54-60.

31. Hill DA, Dudley JW, Spergel JM. The prevalence of eosinophilic esophagitis in pediatric patients with IgE-mediated food allergy. J Allergy Clin Immunol Pract. 2017;5:369-375.

32. Hill DA, Grundmeier RW, Ramos M, et al. Eosinophilic esophagitis is a late manifestation of the allergic march. J Allergy Clin Immunol Pract. 2018;6(5):1528-1533.

33. Ruffner M, Cianferoni A. Phenotypes and endotypes in eosinophilic esophagitis. Ann Allergy Asthma Immunol. 2020;124:233-239.

34. Mishra A, Hogan SP, Brandt EB, et al. An etiological role for aeroallergens and eosinophils in experimental esophagitis. J Clin Invest. 2001;107:83-90.

35. Wells R, Fox A, Furman M. Recurrence of eosinophilic esophagitis with subcutaneous grass pollen immunotherapy. BMJ Case Rep. 2018;2018:bcr2017223465. https://doi.org/10.1136/BCR-2017-223465

36. Béné J, Ley D, Roboubi R, et al. Eosinophilic esophagitis after desensitization to dust mites with sublingual immunotherapy. Ann Allergy Asthma Immunol. 2016;116:583-584.

37. Loizou D, Enav B, Komlodi-Pasztor E, et al. A pilot study of omalizumab in eosinophilic esophagitis. PLoS One. 2015;10(3):e0113483.

38. Clayton F, Fang JG, Gleich GJ, et al. Eosinophilic esophagitis in adults is associated with IgG4 and not mediated by IgE. Gastroenterology. 2014;147:602-609.

39. Pesek R, Greuter T, Lopez-Nunez O, et al. Clinicopathological correlations in eosinophilic gastrointestinal disorders. J Allergy Clin Immunol Pract. 2021;9:3258-3266.

40. Guajardo JR, Plotnick LM, Fende JM, et al. Eosinophil-associated gastrointestinal disorders: a world-wide-web based registry. J Pediatr. 2002;141(4):576-581.

41. Iwamuro M, Murakami T, Tanaka T, et al. Eosinophilic gastritis in a patient previously treated with dupilumab. Case Rep Gastrointest Med. 2020;2020:20581670. https://doi.org/10.1155/2020/6381670

42. Han D, Lee JK. Severe asthma with eosinophilic gastroenteritis effectively managed by mepolizumab andomalizumab. Ann Allergy Asthma Immunol. 2018;121(6):742-743.
43. Ko H, Morotti R, Yershov O, et al. Eosinophilic gastritis in children: clinicopathological correlation, disease course, and response to therapy. *Am J Gastroenterol.* 2014;109:1277-1285.

44. Reed C, Woosley JT, Dellon ES. Clinical characteristics, treatment outcomes, and resource utilization in children and adults with eosinophilic gastroenteritis. *Dig Liver Dis.* 2015;47:197.

45. Raffaele A, Vatta F, Votto M, et al. Eosinophilic colitis in children: a new and elusive enemy? *Pediatr Surg Int.* 2021;37:485-490.

46. Impellizzeri G, Marasco G, Eusebi LH, et al. Eosinophilic colitis: a clinical review. *Dig Liver Dis.* 2019;51:769-773.

47. Díaz del Arco C, Taxonera C, Olivares D, et al. Eosinophilic colitis: case series and literature review. *Pathol Res Pract.* 2018;214:100-104.

48. Behjati S, Zilbauer M, Heuschkel R, et al. Defining eosinophilic colitis in children: insights from a retrospective case series. *J Pediatr Gastroenterol Nutr.* 2009;49:208-215.

49. Rossi C, Lentí M, Merli S, et al. Allergic manifestations in autoimmune gastrointestinal disorders. *Autoimmun Rev.* 2022;21(1):102958. https://doi.org/10.1016/j.autrev.2021.102958

50. Wright BL, Fernandez-Becker NQ, Kambham N, et al. Baseline gastrointestinal eosinophilia is common in oral immunotherapy subjects with IgE-mediated peanut allergy. *Front Immunol.* 2018;9:1-12.

51. Eckmann JD, Ravi K, Katzka DA, et al. Efficacy of atopy patch testing in directed dietary therapy of eosinophilic esophagitis: a pilot study. *Dig Dis Sci.* 2018;63:694-702.

52. Burk CM, Dellon ES, Steele PH, et al. Eosinophilic esophagitis during peanut oral immunotherapy withomalizumab. *J Allergy Clin Immunol Pract.* 2017;5:498-501.

53. Sealock RJ, Kramer JR, Verstovsek G, et al. The prevalence of oesophageal eosinophilia and eosinophilic oesophagitis: a prospective study in unselected patients presenting to endoscopy. *Aliment Pharmacol Ther.* 2013;37:825-832.

54. Joo MK, Park J, Kim S, et al. Original article prevalence and endoscopic features of eosinophilic esophagitis in patients with esophageal or upper gastrointestinal symptoms. *J Dig Dis.* 2012;13(6):296-303.

55. Debroas CW, Franciosi JP, King EC, et al. Long-term outcomes in pediatric-onset eosinophilic esophagitis. *J Allergy Clin Immunol.* 1999;128:132-138.

56. García-compeán D, Alberto J, González G, et al. Prevalence of eosinophilic esophagitis in patients with refractory gastroesophageal reflux disease symptoms: a prospective study. *Dig Liver Dis.* 2011;43:204-208.

57. Ravi K, Talley NJ, Smyrk TC, et al. Low grade esophageal eosinophilia in adults: an unrecognized part of the spectrum of eosinophilic esophagitis. *Dig Dis Sci.* 2011;56(7):1981-1986.

58. Foroutan M, Norouzi A, Molaei M, et al. Eosinophilic esophagitis in patients with refractory gastroesophageal reflux disease. *Dig Dis Sci.* 2010;55:28-31.

59. Veerappan GR, Perry JL, Duncan TJ, et al. Prevalence of eosinophilic esophagitis in an adult population undergoing upper endoscopy: a prospective study. *Clin Gastroenterol Hepatol.* 2009;7:420-426.

60. Mackenzie SH, Go M, Chadwick B, et al. Eosinophilic oesophagitis in patients presenting with dysphagia - a prospective analysis. *Aliment Pharmacol Ther.* 2008;28:1140-1146.

61. Votto M, Raffele A, De Filippo M, et al. Eosinophilic gastrointestinal disorders in children and adolescents: a single-center experience. *Dig Liver Dis.* 2022;54:214-220.

62. Leung AJT, Persad S, Slae M, et al. Intestinal and gastric permeability in children with eosinophilic esophagitis and reflux esophagitis. *J Pediatr Gastroenterol Nutr.* 2015;60:236-239.

63. Fuentes-Aparicio V, Alvarez-Perea A, Infante S, et al. Specific oral tolerance induction in paediatric patients with persistent egg allergy. *Allergol Immunopathol.* 2013;41:143-150.

64. Slae M, Persad R, Leung AJT, et al. Role of environmental factors in the development of pediatric eosinophilic esophagitis. *Dig Dis Sci.* 2015;60:3364-3372.

65. Jensen ET, Kappelman MD, Kim HP, et al. Early life exposures as risk factors for pediatric eosinophilic esophagitis. *J Pediatr Gastroenterol Nutr.* 2013;57:67-71.

66. Sánchez-García S, Rodríguez Del Río P, Escudero C, et al. Possible eosinophilic esophagitis induced by milk oral immunotherapy. *J Allergy Clin Immunol.* 2012;129:1155-1157.

67. Ridolo E, De Angelis GL, Dall’Aglio P. Eosinophilic esophagitis after specific oral tolerance induction for egg protein. *Ann Allergy Asthma Immunol.* 2011;106:73-74.

68. Cassell H, Mukkada VA, Woodruff SA, et al. Allergic diseases in children with eosinophilic esophagitis (EoE) compared to gastroesophageal reflux disease (GERD). *Gastroenterology.* 2009;136:284-285.

69. Aceves SS, Newbury RO, Dohil MA, Bastian JF, Dohil R. A symptom scoring tool for identifying pediatric patients with eosinophilic esophagitis and correlating symptoms with inflammation. *Ann Allergy Asthma Immunol.* 2009;103:401-406.

70. Hofmann AM, Scurlack AM, Jones SM, et al. Safety of a peanut oral immunotherapy protocol in peanut allergic children. *J Allergy Clin Immunol.* 2009;124:286-291.

71. Sugnannam KK, Collins JT, Smith PK, et al. Dichotomy of food and inhalant allergen sensitization in eosinophilic esophagitis. *Allergy.* 2007;62:1257-1260.

72. Duffey H, Peterson K, First R. Population-based study suggests strong genetic association between eosinophilic esophagitis and asthma. *J Allergy Clin Immunol.* 2016;137:AB400.

73. Peterson K, Fang JC, First R. Familial risk of eosinophilic gastro-intestinal disorders (EGID) and atopy in eosinophilic esophagitis (EoE). *Gastroenterology.* 2015;148:S-414.

74. Mansoor E, Cooper G. Epidemiology of eosinophilic esophagitis in the United States: a population based study. *Am J Gastroenterol.* 2015;110:S693-S694.

75. Zafra MP, Cancelliere N, Rodríguez Del Río P, et al. Misregulation of suppressors of cytokine signaling in eosinophilic esophagitis. *J Gastroenterol.* 2013;48:910-920.

76. Dellon ES, Gibbs WB, Fritchie KJ, et al. Clinical, endoscopic, and histologic findings distinguish eosinophilic esophagitis from gastroesophageal reflux disease. *Clin Gastroenterol Hepatol.* 2009;7:1305-1313.

77. Spergel JM. An allergist’s perspective to the evaluation of eosinophilic esophagitis. *Best Pract Res Clin Gastroenterol.* 2015;29:771.

78. Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. *Lancet.* 2020;396:345-360.

79. Cevhertas L, Ogulur I, Maurer DJ, et al. Advances and recent developments in asthma in 2020. *Allergy.* 2020;75:3124-3146.

80. Dellon E, Peterson K, Murray J, et al. Anti-Siglec-8 antibody for eosinophilic gastritis and duodenitis. *N Engl J Med.* 2020;383:1624-1634.

81. Schanin J, Gebremeskel S, Korver W, et al. A monoclonal antibody to Siglec-8 suppresses non-allergic airway inflammation and inhibits IgE-independent mast cell activation. *Mucosal Immunol.* 2021;14:366-376.

82. Rossi CM, Lenti MV, Di Sabatino A. The need for a reliable non-invasive diagnostic biomarker for eosinophilic esophagitis. *Lancet Gastroenterol Hepatol.* 2022;7:202-203.

---

**How to cite this article:** Rossi CM, Lenti MV, Merli S, et al. Primary eosinophilic gastrointestinal disorders and allergy: Clinical and therapeutic implications. *Clin Transl Allergy.* 2022; e12146. https://doi.org/10.1002/ctla.12146